Search This Blog

Wednesday, January 25, 2023

Preeclampsia linked with four-fold higher risk of heart attack in decade after childbirth

 Women with preeclampsia develop a higher likelihood of heart attack and stroke than their peers within just seven years of delivery, with risks remaining elevated more than 20 years later. The study of more than one million pregnant women is published today in the European Journal of Preventive Cardiology.

"The high risk of  after preeclampsia manifests at young ages and early after delivery," said study author Dr. Sara Hallum of the University of Copenhagen, Denmark. "This indicates that interventions to prevent heart attacks and strokes in affected women cannot wait until  when they become eligible for conventional cardiovascular screening programs."

Preeclampsia affects up to 8% of pregnancies worldwide. Medical signs are high blood pressure and protein in the urine, which develop after 20 weeks of  or soon after delivery. Symptoms include severe headache, stomach pain and nausea. "Women may mistake these for 'normal' pregnancy symptoms and thus not seek  until the condition becomes severe," said Dr. Hallum. "Most cases are mild, but preeclampsia may lead to serious complications for the mother and baby if not treated in time."

It is well established that preeclampsia predisposes women to an elevated likelihood of cardiovascular disease later in life. This was the first study to examine how soon after pregnancy these heart attacks and strokes manifest, and the magnitude of risk in different age groups.

National registers were used to identify all  in Denmark between 1978 and 2017. Women were grouped into those with one or more pregnancies complicated by preeclampsia and those with no preeclampsia. Participants were free of cardiovascular disease before pregnancy and were followed for a maximum of 39 years for  and stroke. Dr. Hallum said, "This allowed us to evaluate exactly when cardiovascular disease occurs in women with and without preeclampsia, and to estimate risk in different age groups and at various durations of follow-up."

The study included 1,157,666 women. Up to 2% of those with preeclampsia in their first pregnancy had a heart attack or stroke within two decades of delivery, compared with up to 1.2% of unaffected women. Differences in risk became apparent seven years after delivery. "A 2% incidence of acute myocardial infarction and ischemic stroke should not be accepted as the cost of a pregnancy complicated by preeclampsia, particularly considering the young age of these women when they fall ill (below 50 years of age)," states the paper.

Overall, women with preeclampsia were four times more likely to have a heart attack and three times more likely to have a stroke within 10 years of delivery than those without preeclampsia. The risk of heart attack or stroke was still twice as high in the preeclampsia group more than 20 years after giving birth, compared to unaffected women.

When the researchers examined the risk of cardiovascular disease according to age, they found that women aged 30 to 39 years with a history of preeclampsia had five- and three-fold higher rates of heart attack and , respectively, than those of similar age with no history of preeclampsia. The raised likelihood of cardiovascular disease in those with a history of preeclampsia persisted throughout adulthood, with women over 50 years of age still at doubled risk compared to their peers with no history of the pregnancy complication.

Dr. Hallum said, "Women are often in contact with the healthcare system during and immediately after pregnancy, providing a window of opportunity to identify those at increased risk of cardiovascular disease. The number of women with previous preeclampsia is large, and routine follow-up could last years or even decades. Our study suggests that the women most likely to benefit from screening are those who had preeclampsia after age 35 and those who had it more than once. Prevention should start within a decade of delivery, for example, by treating  and informing women about risk factors for heart disease, such as smoking and inactivity."

More information: Sara Hallum et al, Risk and trajectory of premature ischemic cardiovascular disease in women with a history of preeclampsia: a nationwide register-based study, European Journal of Preventive Cardiology (2023). DOI: 10.1093/eurjpc/zwad003


https://medicalxpress.com/news/2023-01-preeclampsia-mothers-linked-four-fold-higher.html

Paul Pelosi sold Google shares prior to DOJ antitrust suit

 Paul Pelosi, the multimillionaire husband of former House Speaker and current Rep. Nancy Pelosi (D-Calif), sold 30,000 shares of Google stock a month prior to the Dept. of Justice's announcement of an antitrust lawsuit against the tech giant, according to a financial disclosure filed with the House of Representatives.

Pelosi reported the sale of Google stock in three different transactions between Dec. 20 and 28, 2022, each of which involved the sale of 10,000 shares of stock in Google's parent corporation Alphabet Inc. The Periodic Transaction Report filed with the House notes that each transaction involved an amount between $500,001 and $1,000,000 and yielded capital gains of more than $200 – although it's unclear how large the profit was. Taken together, the trades involved 30,000 shares and between $1.5 million and $3 million of assets.

The U.S. Dept. of Justice (DOJ) and eight states announced a lawsuit against Google on Tuesday, Jan. 24, alleging that the company engaged in anticompetitive behavior and exercised a monopoly over internet search traffic. 

"Google’s anticompetitive behavior has raised barriers to entry to artificially high levels, forced key competitors to abandon the market for ad tech tools, dissuaded potential competitors from joining the market, and left Google’s few remaining competitors marginalized and unfairly disadvantaged," DOJ and the eight states allege.

The Pelosi family's stock transactions have attracted scrutiny in recent years. Prior to Congress' passage of the CHIPS Act last year, which was ultimately signed into law and provided a roughly $52 billion subsidy to boost domestic computer chip production, Paul Pelosi bought between $1 million and $5 million in shares of Nvidia. 

In July 2022, a spokesman for then-Speaker Pelosi's office told FOX Business that she "does not own any stocks" and "has no prior knowledge or subsequent involvement in any transactions."

placeholder

The spokesman said that Pelosi asked the House committee tasked with regulating members' financial disclosures to "examine the issue of Members' unacceptable noncompliance with the reporting requirements in the STOCK Act, including the possibility of stiffening penalties." Legislation to ban members of Congress from trading stocks stalled at the end of the 117th Congress, although lawmakers have since reintroduced proposals on the subject.

Pelosi's office did not immediately respond to FOX Business' request for comment on this story.

Sen. Josh Hawley (R-Mo.) introduced the Preventing Elected Leaders from Owning Securities and Investments (PELOSI) Act this week, which would ban lawmakers in Congress from stock trading. Hawley reacted on Twitter to the news about the Pelosi family's latest stock trade:

Efforts to increase oversight and promote transparency into lawmakers' investments increased after revelations that then-Sen. Richard Burr (R-N.C.) abruptly sold hundreds of thousands of dollars from his investment portfolio after he received a closed-door briefing in February 2020 on the potential impact of the COVID-19 pandemic. 

Burr was investigated by the Securities and Exchange Commission (SEC) over the trades and announced earlier this month that ended its probe without taking action against him.

It's unclear if the current Congress will hold votes on legislation related to the dealings of lawmakers and their families on financial markets. One of the main laws on the subject that is currently on the books is the Stop Trading on Congressional Knowledge (STOCK) Act of 2012 which requires lawmakers to report stock trades to Congress within 45 days of completing a transaction. 

The law also prohibited the use of non-public information for private profit, including insider trading by members of Congress and other government employees.

https://www.foxbusiness.com/politics/paul-pelosi-sold-google-shares-prior-doj-antitrust-suit

Biden 'Dietary Expert' Claims Willpower Doesn't Exist And Obesity Is A 'Brain Disease'

 by Ben Bartee via PJMedia.com,

Dr. Fatima Stanford, who sits on Biden’s 2025 Dietary Guidelines Advisory Committee, appeared on corporate media to share her lived experiences as a fat propagandist.

Here are the highlights of Stanford’s remarkably detached-from-reality obesity religion masquerading as science:

  • “[Obesity] is a brain disease.”

  • “Throw [willpower] out the window.”

  • “The number one cause of obesity is genetics. That means if you were born to parents that have obesity, you have a 50-85% likelihood of having the disease yourself even with optimal diet, exercise, sleep management, stress management, so when people see families that have obesity, the assumption is, ‘Ugh. What are they feeding those kids? They’re doing something wrong.'”

  • “Doctors do not understand obesity.”

To summarize the tenets of the faith, fat children (who are getting fatter by the year) of fat parents are fat because of genetics, not because the whole family eats the same GMO-processed slop.

Doctors have biases against obese people, and they also don’t understand obesity.

Loving and liberal tolerance is not about tolerance but about enabling destructive behaviors that weaken society and, as a result, any potential resistance to the power structure.

Fat people are probably too depressed and downtrodden and wheezy to put up a fight.

Plus, if they can keep you in the “sweet spot” of barely alive, the medical industry can extract all of the fats’ wealth with their products and services while they slowly expire.

You’ll be scandalized and flabbergasted to learn that the good doctor is actually a paid pharmaceutical shill — or, as the New York Times more delicately puts it, “Dr. Stanford has served as an adviser for a number of pharmaceutical companies, a common practice for experts in the field.”

https://www.zerohedge.com/medical/biden-dietary-expert-claims-willpower-doesnt-exist-and-obesity-brain-disease

The Banality of Good

 It might have been expected that the first scholarly study of what has happened in our society over the past few years should hail from abroad, where nonwoke discourse remains far freer. Mattias Desmet has said that his 2022 book The Psychology of Totalitarianism was received with some caution in his home country of Belgium, but he has yet to suffer any consequences in his career as an academic clinical psychologist and practicing psychotherapist. Tellingly, his book’s English translation was not picked up by any notable American or British publisher, virtually all of which are reliably woke, but by rural Vermont’s Chelsea Green Publishing, a small employee-owned and self-distributing house whose books are mainly about sustainable craft farming. From this humble entry into the marketplace of ideas, Desmet has won right-wing celebrity and attracted attention from such prominent media personalities as Tucker Carlson and Joe Rogan. His book has topped Amazon’s bestseller lists in relevant political science categories, consistently exceeding sales of similar recent books by Timothy Snyder, Jason Stanley, Rod Dreher, Ruth Ben-Ghiat, and even the perennially popular classics by Friedrich Hayek, Robert Paxton, and Hannah Arendt, whose Totalitarianism (1951) is the jumping-off point for Desmet’s analysis.

Desmet seeks to improve upon Arendt’s thesis with the argument that the “soft” totalitarianism she predicted would evolve after the horrors of Nazism and Stalinism is now a nightmare come true. Our current tyranny is not the menacing dictatorships of old, which were built on fear and operated by compliant functionaries practicing banalized evil, but by a subtler regime enforced by “dull bureaucrats and technocrats” convinced that they are advancing a greater good for humanity. The new agents of persecution are not jackbooted secret police thugs instilling fear, but almond milk latte-swigging university officials imposing unpleasant consensus. George Orwell’s vicious O’Brien has yielded to Ken Kesey’s passive-aggressive Nurse Ratched.

Much of the book dwells on how we got here. Desmet traces the evolution of human societies from the scientific revolution, when free inquiry battled with religious dogma to understand the natural world per se. Confirmed by the Enlightenment’s triumphant claims to have found the correct path forward, not merely for science but for society, we entered a modern era defined by what he calls a “mechanistic ideology” that held out “the utopian vision of an artificial paradise” as a perfect, and inevitable, future. The universe and everything in it, to the purely scientific mind, thus follows impersonal patterns and motions that science alone can reveal. Potentially, this offered humans immense power and insight, but it also reduced them to existence without meaning or purpose. As a result, industrial economies instrumentalized people, separating them from community, traditions, imagination, nature, emotions, the fruits of their labor, and other factors that had once made life worth living. As a result, atomized individuals developed a generalized and unmoored anxiety that could be resolved when focused on an object or scapegoat that was assigned responsibility for their plight. Collectively blaming a common object of loathing primed these populations for rule by “masters,” leaders who played to their atavism to build a new society united by little more than submission to their generalized authority.

This process of “mass formation” allowed early totalitarians to appeal to science or, more likely pseudoscience, to justify the new status quo and carry out outrages and absurdities. Those regimes, however, were isolated, short-lived, and prone to internal collapse. The new totalitarianism of which Desmet warns is far more pervasive. As science and technology exploded in recent decades, popular faith in them “tipped from open-mindedness to belief.” The values of free inquiry and spirited debate, of regarding hypotheses merely as assertions that had yet to be disproved, were overwhelmed by a new dogma determined not by priests, but by practitioners. For those who followed, “science became ideology.”

Desmet’s notion that mass formation, and consequently totalitarianism, “are in fact symptoms of the mechanistic ideology” struck him strongly during the COVID-19 pandemic. Globalized information technology not only helped spread the virus, but also united the world in what he calls a “Great Leap Forward” toward “totalitarian technocracy.” Confined to near house arrest, with strict limitation on mobility and human contact, a new and purer form of atomization seized the minds of anxious publics looking for enemies to blame and dissenters to punish. “Never before were the societal conditions so prone to totalitarianism,” Desmet argues, as they have been in the last few years. To add empirical insult to psychological injury, many establishment precepts initially advanced as irrefutably sound turned out to be exaggerated, contingent, harmful, and, in some cases, simply wrong, with little or no accountability for individuals and institutions that had erred but still clung to authority.

Despite these deficiencies, a confused and traumatized bulk of society still indulged in “a kind of intoxication” in their new sense of belonging. As we saw all too often in our own country, those who shamed the unmasked or unvaxed, who snitched on their neighbors for noncompliance, who kept schools and places of worship closed, were formed into a new mass “convinced of their superior ethical and moral intentions and of the reprehensibility of everything and everyone who resists them.”

One might quibble with Desmet’s arguments about the extent to which “the Science™” got things wrong, or riposte that the unknown severity of the virus excused overreach, but it is difficult to argue that the pandemic fundamentally accelerated extant trends in how our society is monitored, who has overweening authority over it, and what the consequences of noncompliance can be. The book might have enjoyed even greater success if Desmet had considered the complementary woke phenomena ushered in by the #MeToo movement, critical race theory, radical gender ideology, and their consequences for free speech and behavior. Like COVID and its performative safetyism, all of those orthodoxies advanced broad social controls based on emotion, anxiety, and shaky data, much of which have also been exposed as exaggerated or fraudulent. Strikingly, they emerged in the Anglosphere at times that overlapped with the pandemic. The technocratic authorities who enforced them were similarly bland, bureaucratized, and in most cases protected from any significant liability. We might forgive Desmet for leaving them out, however, for the collective hysteria around race, gender, and sex did not travel well outside of the English-speaking world.

The question we should all be rushing to answer, of course, is how to fight back. Desmet parrots the standard middle-class professional’s argument that dissidents should speak out, but only in polite, sincere ways that avoid antagonizing the dominant ideology. His hope is that this will penetrate the mass formation sufficiently to expose its dynamics to broad majorities who go along with it without necessarily believing in it. He would know better if that could work in Belgium, but Americans have already amassed decades of evidence showing that this spells failure, if not disaster. However strongly worded their letters may have been, polite dissenters have proved remarkably easy to ignore for at least the last 50 years. Meanwhile, increasingly powerful woke mandarins have implemented their agenda of social control, long secure in the knowledge that their opponents were little more than gracious losers. Like him or not, it took the abrasive Donald Trump and his army of “deplorables” to challenge this dismal outcome with considerable success, through aggressive media activism, the majesty of the law, and perhaps most significantly, ridicule that no tyranny can withstand.

That phenomenon might merit study if Desmet wishes to examine the question of what should come next, but he favors a far more idealistic solution. Perhaps predictably, he places a great deal of faith in his own academic discipline, advocating for a more psychological than physical or biological approach to the human condition. “The real task facing us,” he writes, “is to construct a new view of man and the world, to found a new foundation for our identity, to formulate new principles for living together with others, and to reappraise a timely human capacity—speaking the truth.” He may be comforted to know that more and more people across the Atlantic are now doing precisely that, over the furious opposition of our would-be totalitarian rulers, who believe truth is a monopoly that belongs to them.

Paul du Quenoy is the President of the Palm Beach Freedom Institute.

https://www.tabletmag.com/sections/arts-letters/articles/banality-of-good-mattias-desmet-totalitarianism

Magenta Pauses Phase 1/2 Trial After Patient Death

 Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117. The known information has been reported to the U.S. Food and Drug Administration (FDA) as a Suspected Unexpected Serious Adverse Reaction (SUSAR). After consultation with the trial’s safety Cohort Review Committee and with the highest regard for patient safety, Magenta has voluntarily paused dosing in the clinical trial and is working to evaluate the totality of available data and determine next steps for the development of MGTA-117.

https://finance.yahoo.com/news/magenta-therapeutics-voluntarily-pauses-mgta-210500940.html

Ocuphire Misses Topline in Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy

 “Our goals in this initial retina Phase 2 trial were to explore multiple endpoints to evaluate the potential for APX3330 as the first oral drug to safely benefit diabetic patients with eye disease,” said Mina Sooch, MBA, founder and CEO of Ocuphire Pharma. “Although we did not meet the primary endpoint (a precedented endpoint for local administration of anti-VEGF intravitreal injections), we are pleased that the ZETA-1 results on key pre-specified endpoints demonstrated positive outcomes with a favorable systemic and ocular safety profile that support our plans to move forward to an End-of-Phase 2 meeting with the FDA. Given the systemic delivery of APX3330, it is important to evaluate its effect on both eyes. APX3330 achieved statistical significance on a key pre-specified secondary endpoint – binocular 3-step or more worsening of DRSS (diabetic retinopathy severity score) – a clinically meaningful outcome that demonstrates the ability to slow the worsening of this progressive disease and is a potential Phase 3 registration endpoint. With the financial strength provided by our recent global Nyxol® license agreement, we have considerable flexibility to design and initiate the pivotal stage of the APX3330 program. We thank the study participants, clinical investigators and their site staffs for participating in the trial.”

Juul in deal talks with three tobacco giants

 Juul Labs Inc. is looking for a new partner. 

The e-cigarette maker, which came close to filing for bankruptcy protection last fall, is now in early-stage talks with three tobacco giants, according to people familiar with the matter. Juul is seeking a potential sale, strategic-investment, licensing or distribution deal, the people said.

Juul executives in recent weeks have had separate discussions with Philip Morris International Inc., Japan Tobacco Group and Altria Group Inc., the people said. A deal isn’t imminent, the people said, and the discussions might not result in a sale or partnership. Altria, which owns a 35% stake in Juul, valued the vaping company at $1 billion in October.

Juul, which represents 27% of e-cigarettes sold in U.S. stores tracked by Nielsen, reached the brink of bankruptcy last year amid a dispute with federal regulators over whether its products could remain on the U.S. market. The still-unresolved dispute made it difficult for Juul to raise money to cover its legal liabilities. 

TickerSecurityLastChangeChange %
PMPHILIP MORRIS INTERNATIONAL INC.103.42+2.12+2.09%
MOALTRIA GROUP INC.44.93+0.15+0.33%

Juul in December agreed to pay $1.7 billion in a broad legal settlement covering more than 5,000 lawsuits. Many of the lawsuits accused the e-cigarette maker of marketing its products to children and teens. Juul has said it never targeted young people and has been working to regain the trust of regulators and the public.

To pay for the settlement, Juul secured an equity investment from a group including two Juul directors, The Wall Street Journal has reported. The settlement and financing put Juul on firmer ground and allowed the company to begin talks with potential strategic partners. 

Juul reached late-stage talks with Altria last fall on a potential deal to sell Juul’s international business or license its U.S. intellectual property but those talks fell apart in September as Juul prepared for a potential bankruptcy filing, people familiar with the discussions said. Those talks haven’t previously been reported. 

placeholder

Altria on Sept. 30 announced it was ending its noncompete agreement with Juul. The decision gave the Marlboro maker the flexibility to acquire another e-cigarette brand or develop its own new vaping products. And it gave Juul the freedom to sell itself—or a significant stake—to one of Altria’s competitors. 

Juul Chief Executive K.C. Crosthwaite and other Juul executives traveled this month to Switzerland, where both Japan Tobacco and Philip Morris are based, to discuss Juul’s newly expanded options, some of the people familiar with the matter said. 

Juul has also resumed discussions with Altria, these people said. Altria can’t buy Juul outright because of antitrust concerns: In a case that is pending, the Federal Trade Commission is seeking to unwind Altria’s 2018 investment in Juul. Altria and Japan Tobacco in October formed a partnership to develop and sell heated tobacco devices in the U.S. and other new tobacco products abroad.

Altria sells Marlboro cigarettes in the U.S., while its erstwhile partner Philip Morris sells Marlboros outside the U.S. The companies split in 2008.  Philip Morris now plans to re-enter the U.S. market through its acquisition of Swedish Match.

The Food and Drug Administration in June ordered Juul to take its products off the U.S. market, then stayed the order pending Juul’s appeal. If the FDA ultimately rejects Juul’s e-cigarettes, Juul could seek U.S. authorization for a newer version of its vaporizer that so far has been released in Canada and the U.K. Juul also has other products under development.

https://www.foxbusiness.com/markets/juul-deal-talks-three-tobacco-giants